EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyse

Blood Pressure-Lowering Effects of Aldosterone Synthase Inhibitors in Uncontrolled or Resistant Hypertension: A Systematic Review and Meta-Analysis of Recent Randomized Controlled Trials

Girin Ray, Debmalya Sanyal

Archives of Endocrinology and Disorders · 2026

DOI: 10.46889/aed.2026.2303 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Archives of Endocrinology and Disorders, 2026. Verfasst von Girin Ray und 1 weiteren Autor:innen. Die Arbeit nennt 10 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The overproduction of aldosterone is an important cause of uncontrolled or resistant hypertension. Conversely, aldosterone synthase inhibitors including baxdrostat and lorundrostat have an upstream effect blocking aldosterone synthesis. The overproduction of aldosterone causes many drug resistant hypertensive diseases. Agents that act at the Mineralocorticoid Receptor (MR), i.e., MR Antagonists (MRAs) such as spironolactone and eplerenone block signalling downstream of aldosterone, thereby inducing BP lowering effects. Conversely, aldosterone synthase inhibitors inculding baxdrostat and lorundrostat have an upstream effect at the aldosterone level, thereby specifically reducing the production of aldosterone in the adrenal cortex.

Objective

This systematic review and meta-analysis of recent (2020-2025) RCTs on blood pressure-lowering evidence for ASIs and established MRAs. The 2020-2025 records published were included in accordance with PRISMA 2020 orientation (Pubmed, Scopus, Web of Science, Cochrane CENTRAL, ClinicalTrials.gov). Eligible recent (2020-2025) randomized controlled trials in adults with hypertension reporting impact on Systolic Blood Pressure (SBP) or Diastolic Blood Pressure (DBP) were included. Placebo-adjusted mean differences in mmHg data was assessed, using random-effects meta-analysis where summary confidence intervals available. Outcomes: Eight contemporary RCT reports qualified for qualitative synthesis and five ASI RCT reports were incorporated as dose-level estimates in quantitative synthesis. The combined effect of ASI was a reduction in SBP by almost -8.82 mmHg (95% CI, -10.46 to -7.18; I2 from dose-level summaries = moderate) and a reduction in DBP by almost -4.25 mmHg (95% CI, -5.33 to -3.18). The two drugs, Baxdrostat and lorundrostat, produced clinically meaningful reductions, especially in those with uncontrolled or resistant hypertension. No new 2020-2025 RCT directly comparing spironolactone or eplerenone against ASIs was identified; therefore, class comparison is indirect and must be interpreted cautiously. Overall, ASIs have strong short-term placebo-adjusted effects on BP. MRAs are the standard add-on therapy of resistant hypertension, but direct RCT comparisons between ASIs and MRAs are required.

Zitieren

APA

Ray, G., & Sanyal, D. (2026). Blood Pressure-Lowering Effects of Aldosterone Synthase Inhibitors in Uncontrolled or Resistant Hypertension: A Systematic Review and Meta-Analysis of Recent Randomized Controlled Trials. Archives of Endocrinology and Disorders. https://doi.org/10.46889/aed.2026.2303

Vancouver

Ray G, Sanyal D. Blood Pressure-Lowering Effects of Aldosterone Synthase Inhibitors in Uncontrolled or Resistant Hypertension: A Systematic Review and Meta-Analysis of Recent Randomized Controlled Trials. Archives of Endocrinology and Disorders. 2026. doi:10.46889/aed.2026.2303

BibTeX
@article{Ray2026,
  author = {Ray, Girin and Sanyal, Debmalya},
  title = {Blood Pressure-Lowering Effects of Aldosterone Synthase Inhibitors in Uncontrolled or Resistant Hypertension: A Systematic Review and Meta-Analysis of Recent Randomized Controlled Trials},
  journal = {Archives of Endocrinology and Disorders},
  year = {2026},
  doi = {10.46889/aed.2026.2303}
}
Kostenlos starten →